VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Don’t worry, be happy! Finding spiritual relief from Parkinson’s
Love, fulfilment and altruism have the power to reduce symptoms
2 days ago
Can a digital pen “revolutionise” Parkinson’s diagnosis?
A Parkinson’s diagnosing pen has sealed a five-year manufacturing deal from stationery brand Stabilo. The Neuromotor Pen– developed by Scottish medical devices company Manus Neurodynamica – analyses a user’s hand and limb movements as they perform a number of drawing tests on a tablet. Microchips within the device record the data of even the smallest of movements, and determine whether a user has Parkinson’s in a simple and non-invasive way. Researchers believe the pen could be adapted in the future for use in monitoring patients with Alzheimer’s, multiple sclerosis and those that have suffered from a stroke. Peter Kämpf, director of research and development at Schwan-Stabilo, said: “This novel product can potentially revolutionise the diagnosis and treatment of neuromotor diseases, and we are excited to be involved in its development and in helping bring it to market.”
2 weeks ago
Scotland sees soaring Parkinson’s rate
The number of drugs being prescribed for people living with Parkinson’s in Scotland, UK, has increased by more than a quarter. National Health Service (NHS) figures, published by the Scottish Conservative party, show that the number of items being dispensed for the condition have leapt by 28% – from 260,355 in 2010 to 333,167 in 2019. The sharp rise is thought to be a consequence of Scotland’s ageing population and has prompted calls from bodies, including Parkinson’s UK, for government action to ensure the NHS can cope with the increasing number of Parkinson’s cases. Annie Macleod, director of Parkinson’s UK Scotland, said: “Over the next decade we expect to see numbers increase by a fifth.” She added that reasons for such a spike could include “growing numbers of people living with more complex Parkinson’s, or changes to the ways that specialists are managing Parkinson’s”.
Over a quarter of people living with Parkinson’s were initially misdiagnosed, study finds
More than a quarter of people living with Parkinson’s were initially misdiagnosed, according to new research from charity Parkinson’s UK. As part of the study, 2,000 people with Parkinson’s were asked a series of questions about their diagnosis. According to results, 26% of the participants were originally told they did not have Parkinson’s – with almost half of them being treated for a different condition. The poll also found that women were more likely to be misdiagnosed than men. Katie Goates, professional engagement manager at Parkinson’s UK, said: “One of the biggest challenges for Parkinson’s research is that there is no definitive test for Parkinson’s, and as a result we’ve heard of people being misdiagnosed with anything from a frozen shoulder or anxiety to a stroke. “Our survey has shown that because of this people are being left in limbo and seeing their health deteriorate, which is unacceptable.”